130 related articles for article (PubMed ID: 32779428)
1. Type 4 hypersensitivity development in a case due to mifamurtide.
Şimşek M; Ataş E; Bağrıaçık EÜ; Günal A; Ünay B
Turk J Pediatr; 2020; 62(4):694-699. PubMed ID: 32779428
[TBL] [Abstract][Full Text] [Related]
2. Mifamurtide: osteosarcoma: ineffective and harmful.
Prescrire Int; 2011 Apr; 20(115):89. PubMed ID: 21648206
[TBL] [Abstract][Full Text] [Related]
3. Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.
Anderson PM; Meyers P; Kleinerman E; Venkatakrishnan K; Hughes DP; Herzog C; Huh W; Sutphin R; Vyas YM; Shen V; Warwick A; Yeager N; Oliva C; Wang B; Liu Y; Chou A
Pediatr Blood Cancer; 2014 Feb; 61(2):238-44. PubMed ID: 23997016
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: a systematic review.
Jimmy R; Stern C; Lisy K; White S
JBI Database System Rev Implement Rep; 2017 Aug; 15(8):2113-2152. PubMed ID: 28800058
[TBL] [Abstract][Full Text] [Related]
5. The addition of the immunomodulator mifamurtide to adjuvant chemotherapy for early osteosarcoma: a retrospective analysis.
Kokkali S; Kotsantis I; Magou E; Sophia T; Kormas T; Diakoumis G; Spathas N; Psyrri A; Ardavanis A
Invest New Drugs; 2022 Jun; 40(3):668-675. PubMed ID: 35312944
[TBL] [Abstract][Full Text] [Related]
6. Mifamurtide: a review of its use in the treatment of osteosarcoma.
Frampton JE
Paediatr Drugs; 2010 Jun; 12(3):141-53. PubMed ID: 20481644
[TBL] [Abstract][Full Text] [Related]
7. Muramyl Tripeptide Plus Chemotherapy Reduces Metastasis in Non-Metastatic Osteosarcoma: A Single-Center Experience.
Taçyıldız N; Unal E; Dinçaslan H; Çakmak HM; Köse K; Tanyıldız G; Kartal Ö
Asian Pac J Cancer Prev; 2020 Mar; 21(3):715-720. PubMed ID: 32212798
[TBL] [Abstract][Full Text] [Related]
8. The Role of Mifamurtide in Chemotherapy-induced Osteoporosis of Children with Osteosarcoma.
Bellini G; Di Pinto D; Tortora C; Manzo I; Punzo F; Casale F; Rossi F
Curr Cancer Drug Targets; 2017; 17(7):650-656. PubMed ID: 27993113
[TBL] [Abstract][Full Text] [Related]
9. Orphan drugs revisited: cost-effectiveness analysis of the addition of mifamurtide to the conventional treatment of osteosarcoma.
Brosa M; García del Muro X; Mora J; Villacampa A; Pozo-Rubio T; Cubells L; Montoto C
Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):331-40. PubMed ID: 25354299
[TBL] [Abstract][Full Text] [Related]
10. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma.
Meyers PA
Expert Rev Anticancer Ther; 2009 Aug; 9(8):1035-49. PubMed ID: 19671023
[TBL] [Abstract][Full Text] [Related]
11. The Efficiency and Toxicity of Mifamurtide in Childhood Osteosarcoma.
Tacyildiz N; Incesoy Ozdemir S; Unal E; Berber M; Dincaslan H; Yavuz G
J Pediatr Hematol Oncol; 2018 Aug; 40(6):e373-e376. PubMed ID: 29889801
[TBL] [Abstract][Full Text] [Related]
12. Mifamurtide for high-grade, resectable, nonmetastatic osteosarcoma following surgical resection: a cost-effectiveness analysis.
Johal S; Ralston S; Knight C
Value Health; 2013 Dec; 16(8):1123-32. PubMed ID: 24326165
[TBL] [Abstract][Full Text] [Related]
13. Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine.
Drugs R D; 2008; 9(2):131-5. PubMed ID: 18298131
[TBL] [Abstract][Full Text] [Related]
14. Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma.
Brard C; Piperno-Neumann S; Delaye J; Brugières L; Hampson LV; Le Teuff G; Le Deley MC; Gaspar N
BMJ Open; 2019 May; 9(5):e025877. PubMed ID: 31110092
[TBL] [Abstract][Full Text] [Related]
15. The addition of mifamurtide to chemotherapy improves lifetime effectiveness in children with osteosarcoma: a Markov model analysis.
Song HJ; Lee EK; Lee JA; Kim HL; Jang KW
Tumour Biol; 2014 Sep; 35(9):8771-9. PubMed ID: 24874050
[TBL] [Abstract][Full Text] [Related]
16. Mifamurtide in osteosarcoma--a practical review.
Anderson PM; Tomaras M; McConnell K
Drugs Today (Barc); 2010 May; 46(5):327-37. PubMed ID: 20517534
[TBL] [Abstract][Full Text] [Related]
17. Lifetime effectiveness of mifamurtide addition to chemotherapy in nonmetastatic and metastatic osteosarcoma: a Markov process model analysis.
Song HJ; Lee JA; Han E; Lee EK
Tumour Biol; 2015 Sep; 36(9):6773-9. PubMed ID: 25835978
[TBL] [Abstract][Full Text] [Related]
18. Mifamurtide for the treatment of nonmetastatic osteosarcoma.
Ando K; Mori K; Corradini N; Redini F; Heymann D
Expert Opin Pharmacother; 2011 Feb; 12(2):285-92. PubMed ID: 21226638
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment.
Venkatakrishnan K; Liu Y; Noe D; Mertz J; Bargfrede M; Marbury T; Farbakhsh K; Oliva C; Milton A
Br J Clin Pharmacol; 2014 Jun; 77(6):998-1010. PubMed ID: 24134216
[TBL] [Abstract][Full Text] [Related]
20. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma.
Meyers PA; Chou AJ
Adv Exp Med Biol; 2014; 804():307-21. PubMed ID: 24924182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
